VYNE Therapeutics (VYNE) Stock Price, News & Analysis

Company Overview

VYNE Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for migraine and other central nervous system disorders. Headquartered in Malvern, Pennsylvania, VYNE leverages its proprietary V-Torque™ formulation and delivery technology to enhance the absorption and efficacy of existing active pharmaceutical ingredients. The company’s research and development efforts center on improving patient outcomes while minimizing systemic side effects typically associated with oral therapies.

VYNE’s lead product candidate, Qtrypta™ (zolmitriptan nasal spray), is designed for the acute treatment of migraine attacks in adults. Built on the company’s V-Torque platform, Qtrypta aims to offer rapid onset of action and greater bioavailability compared to currently available nasal formulations. In addition, VYNE markets ZTlido® (lidocaine topical system) for the management of post-herpetic neuralgia, a product licensed from scirepgane partners. ZTlido received U.S. Food and Drug Administration approval in 2018 and has since been distributed through a network of specialty and mail-order pharmacies.

Since its founding in 2015, VYNE has established strategic collaborations to support the clinical advancement and commercialization of its pipeline candidates. The company primarily serves the U.S. market and is preparing for a broader North American roll-out of Qtrypta pending regulatory approvals and market launch preparations. VYNE’s commercial team works closely with healthcare providers, including neurologists and pain specialists, to integrate new treatment options into current practice settings.

Leadership at VYNE Therapeutics is headed by President and Chief Executive Officer Robert Azelby, who brings over two decades of experience in specialty pharmaceuticals and commercialization. The executive team combines expertise in clinical development, regulatory affairs, and commercial operations, underscoring the company’s commitment to delivering innovative therapies for patients with unmet medical needs. VYNE continues to advance its pipeline through late-stage clinical studies while exploring additional indications for its V-Torque technology platform.

Key Stats

• Today's Range: $1.34 to $1.46
• 50-Day Range: $0.89 to $1.77
• 52-Week Range: $0.85 to $4.30
• Volume: 670,275 shs
• Average Volume: 223,735 shs
• Market Capitalization: $21.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.25
• Consensus Rating: Buy

VYNE Therapeutics Stock Analysis - MarketRank™

VYNE Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 622nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

VYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

VYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for VYNE Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of VYNE Therapeutics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VYNE Therapeutics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

VYNE Therapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.46% of the float of VYNE Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

VYNE Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VYNE Therapeutics has recently increased by 45.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VYNE Therapeutics does not currently pay a dividend.

Dividend Growth

VYNE Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.46% of the float of VYNE Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

VYNE Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VYNE Therapeutics has recently increased by 45.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.15

News Sentiment

VYNE Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for VYNE Therapeutics this week, compared to 1 article on an average week.

Search Interest

3 people have searched for VYNE on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of VYNE Therapeutics is held by insiders.

Percentage Held by Institutions

83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VYNE Stock Analysis - Frequently Asked Questions

How have VYNE shares performed this year?

VYNE Therapeutics' stock was trading at $3.35 at the beginning of the year. Since then, VYNE stock has decreased by 57.6% and is now trading at $1.42.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.09. The business earned $0.20 million during the quarter, compared to analyst estimates of $0.05 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 71.89% and a negative net margin of 6,974.55%.

When did VYNE Therapeutics' stock split?

VYNE Therapeutics shares reverse split on Monday, February 13th 2023.The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VYNE
• CIK: 1566044
• Web: vynetherapeutics.com
• Phone: (800) 755-7936
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for VYNE Therapeutics: $6.25
• High Price Target: $8.00
• Low Price Target: $4.50
• Potential Upside/Downside: +340.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.83 million
• Net Margins: -6,974.55%
• Pretax Margin: -6,969.42%
• Return on Equity: -71.89%
• Return on Assets: -58.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.47
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: $500 thousand
• Price / Sales: 43.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.53 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 15,210,000
• Free Float: 14,480,000
• Market Cap: $21.60 million
• Optionable: Not Optionable
• Beta: 1.78